

PTO/SB/01A (10-05) Approved for use through 07/31/2006, OMB 0651-0032 Approved for use through 07/31/2006, UND 003-002

U.S. Potent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Potent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Potent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RADEMARE The Paperwork Reduction Act of 1995, no persone are required to respond to a collection of biformation unless if displays a valid OMB control number.

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of Invention	TISSUE PROTECTIVE CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPSIS AND THE FORMATION OF ADHESIONS					
As the belo	As the below named inventor(s), Vwe declare that:					
This declar	This declaration is directed to:					
,	$\overline{\checkmark}$		ntached application			
	. \square	Applic	cation No.		iled on	400
			As amended on	_		(if applicable);
I/we believe that I/we am/arc the original and first Inventor(s) of the subject matter which is claimed and for which a patent is sought;						
amendme	I/we have reviewed and understand the contents of the above identified application, including the claims, as emended by any amendment specifically referred to above;					
If we have reviewed and understand the contents of the above remainded application in generally referred to above. If we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, Including for continuation-in-part applications, material information which became available between the filling date of the prior application and the national or PCT International filling date of the continuation-in-part application. WARNING: Petitioner/applicant is cautioned to avoid submitting personal information in documents filled in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioner/applicant is should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available. All statements made herein of my/own knowledge are true, all statements made herein on Information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are purishable by fine or Imprisorment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or a						
FULL NAM	ME OF INVENT	OR(S)			-	
Inventor one: MICHAEL BRINES						
Signature	Mu	had	Smit.		Cltizen	of. US
inventor to	NO: ANTHONY C	ERAMI			•	
Signature:					Cltizen	of: US
M Addi	lional inventors or	a legal s	representative are beli	ng named on	7	additional form(s) attached hereto.

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1 minute to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual cases. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ADEMARKS AND ADMINISTRATION AND ADMINISTRATION ADDRESS AND ADMINISTRATION ADDRESS AND ADMINISTRATION ADMINISTR				an ammen ú7/37/2006, ciñiB (a an ammen ú7/37/2006, ciñiB (a an u.s. ues AktiMent of Coi	AMERCE
ADEMA STATE OF THE PARTY OF THE	<u>್ ಆಭ್ಯಕ್ಷಣದ ಚಿತ್ರ (ಆರಂಭಕರ i</u>	ण । स्ट्राट्टल के ज दर्श	ection or information unless	s it contains 8 valid UNIA CO: it is	Cuntoer.
DECLARAT!O		Supplemo	•	Faxe 7	<u></u>
ame of Additional Joint Inventor,	if any:	A PA	ention has been filed to	this unsigned inverted	
Given Alama / Fresh and eviden	(It day))	Family No	we of Granaus		
mas		Coleman			
				Dats	
ventors ignature			us	us	
i Idado	NY State		Country	Citizenship	
Emery Road				•	
Agiling Address	NY		10549	us	
L Kisco	State		Zip	Country	
Name of Additional Joint inventor	r, If any:		petition has been filed t	for this unsigned inventor	
			Family N	ame or Surname	
Given Name (first and middle	B (II BII))				
eman		YEMBZ			,
Inventor's Signature				Date	
Sotteps:	i ≥ा र्गाः		TP.	TR	.1
Residence: City	State		Country	Citizensi	ир
100 Spiked Keleci, Apt. 24/17				•	
Mailing Address	banii '			TR	
Sottepe: City	State	· · · · · · · · · · · · · · · · · · ·	Zip	Country	
Name of Additional Joint Invento	or, if any:		petition has been filed	for this unsigned inventor	
Given Name (first and midd)	e ((f any))		Family N	ame or Sumame	<u></u>
Inventor's Signature				Dete	•
Residence: City	State		Country	Citizens	hlp

City

State

Country

This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 (and by the USPTO to process) an application. Confidentiality is governed by 25 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USPTO. Time will take 21 (and the USPTO time of the USP

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/81 (01-06)
Approved for use through 12/31/2008. OMB 0651-0035
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/573,905		
Filing Date	March 29, 2006		
First Named Inventor	Michael Brines		
Title	Tissue Protective Cytokines for the		
Art Unit	TBD		
Examiner Name	TBD		
Attorney Docket Number	WP03-1A04-US		

I hereby revoke all previous powers of attorney given in the	e above-identified application.						
I hereby appoint:							
Practitioners associated with the Customer Number:	61297						
OR							
Practitioner(s) named below:							
Name	Registration Number						
as my/our attorney(s) or agent(s) to prosecute the application identified all Trademark Office connected therewith.	bove, and to transact all business in the United States Patent and						
Please recognize or change the correspondence address for the above-ion	dentified application to:						
The address associated with the above-mentioned Customer No							
OR							
The address associated with Customer Number:							
OR	The address associated with Customer Number: OR						
Firm or Individual Name							
Address							
City	State Zip						
Country Telephone	Email						
I am the:							
Applicant/Inventor.							
Assignee of record of the entire interest. See 37 CFR 3.71.							
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96							
SIGNATURE of Applicant	or Assignee of Record						
Signature frede // Aprile	Date May 30, 2006						
Name Frederick J. Hamble	Telephone (914)762-7586						
Title and Company Corporate Secretary, Warren Pharmaceuticals, Inc							
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.							
*Total of forms are submitted.							

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/96 (12-05) Approved for use through 07/31/2006. OMB 0651-0031

Minder was aperwork Reduction Act of 1995, no persons a	PTO/SB/96 (12-05) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it displays a valid OMB control number.
	MENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: YILMAZ, OSMAN	
Application No./Patent No./Control No.: 10/573.90	5 Filed/Issue Date: March 29, 2006
Entitled: Tissue Protective Cytokines for the Treatmen	t and Prevention of Sepsis and the Formation of Adhesions
Warren Pharmaceuticals, Inc.	, a Corporation
(Name of Assignee) states that it is: 1. the assignee of the entire right, title, and int	(Type of Assignee: corporation, partnership, university, government agency, etc. erest; or
2. an assignee of less than the entire right, title (The extent (by percentage) of its ownership	
in the patent application/patent identified above by	y virtue of either:
	atent application/patent identified above. The assignment was recorded Office at Reel, Frame, or a true copy of the
	atent application/patent identified above, to the current assignee as follows:
Reel, Frame 2. From: The document was recorded in the t	To: United States Patent and Trademark Office at, or for which a copy thereof is attached. To: United States Patent and Trademark Office at Art for which a copy thereof is attached.
Reel, Frame	, or for which a copy thereof is attached.
The document was recorded in the l	To: United States Patent and Trademark Office at Office at, or for which a copy thereof is attached.
Additional documents in the chain of title	are listed on a supplemental sheet.
assignee was, or concurrently is being, submit [NOTE: A separate copy (i.e., a true copy of	tentary evidence of the chain of title from the original owner to the litted for recordation pursuant to 37 CFR 3.11. The original assignment document(s)) must be submitted to Assignment 3, to record the assignment in the records of the USPTO. See MPEP
The undersigned (whose title is supplied below) is	s authorized to act on behalf of the assignee. May 30, 2006
Signature	Date
Frederick J. Ham	ble 914-762-7586
Printed or Typed N	ame Telephone Number
<u>Corporate Secretary, Warren Pha</u>	armaceuticals, Inc.

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ASSIGNMENT

WHEREAS, I, Osman Yilmaz, citizen of Turkey, residing at 100 Sokad Kalaci, Apt. 24/17, Gottepe Izmir Turkey am a co-inventor with Michael Brines, citizen of the U.S.A., residing at 1 Wepawaug Road, Woodbridge Connecticut 06525; Anthony Cerami, citizen of the U.S.A., residing at 58a Heritage Hills Road, Somers, New York 10589; Thomas Coleman, citizen of the U.S.A., residing at 20 Emery Street, Mt. Kisco, New York 10549, of the invention in TISSUE PROTECTIVE CYTOKINES FOR THE TREATMENT AND PREVENTION OF SEPSIS AND THE FORMATION OF ADHESIONS for which we have executed an application for a Patent of the United States

	which is executed on		even date herewith or	
\boxtimes	which is identified by atto	orney d	ocket no. 20528.0008.PRO	

which was filed on September 29, 2003, Application No. 60/506,149

and WHEREAS, Warren Pharmaceuticals, Inc., having an address of 712 Kitchawan Road, Ossining, NY 10562, ASSIGNEE, is desirous of obtaining our entire right, title and interest in, to and under the said invention and the said application:

NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) to us in hand paid, and other good and valuable consideration, the receipt of which is hereby acknowledged, we, the said ASSIGNORS, have sold, assigned, transferred and set over, and by these presents do hereby sell, assign, transfer and set over, unto the said ASSIGNEE, its successors, legal representatives and assigns, our entire right, title and interest in, to and under the said invention, and the said United States application and all divisions, renewals and continuations thereof, and all Patents of the United States which may be granted thereon and all reissues and extensions thereof; and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for said invention in any country or countries foreign to the United States, together with the right to file such applications and the right to claim for the same the priority rights derived from said United States application under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be applicable; and all forms of industrial property protection, including, without limitation, patents, utility models, inventors' certificates and designs which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof;

AND WE HEREBY authorize and request the Commissioner of Patents and Trademarks of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents or other evidence or forms of industrial property protection on applications as aforesaid, to issue the same to the said ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND WE HEREBY covenant and agree that we have full right to convey the entire interest herein assigned, and that we have not executed, and will not execute, any agreement in conflict herewith.

AND WE HEREBY further covenant and agree that we will communicate to the said ASSIGNEE, its successors, legal representatives and assigns, any facts known to us respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, reissue and foreign applications, make all rightful oaths, and generally do everything possible to aid the said ASSIGNEES, their successors, legal representatives and assigns, to obtain and enforce proper protection for said invention in all countries.

IN TESTIMONY WHEREOF, We hereunto set our hands and seals the day and year set opposite our respective signatures.

Date

31.03
, 2006

Osman Yilmaz

Witness

Witness